Respiratory Virus Vaccines

Subjects aged 3--6, 16--17 and 27--50 years were vaccinated with one dose of hemagglutinin influenza virus vaccine. Clinical reactions, hemagglutinationinhibiting (HI) and strain-and type-specific complement-fixing (CF-V and CF-S) antibodies were determined in sera taken before and four weeks after vaccine administration. The results indicated that the reactogenicity of the vaccine was very low. The HI antibody response differed With the age of the vaceinees, apparently being conditioned by prior exposure to the various influenza virus subtypes. The results of CF tests using strain-specific V antigens corresponded in general with HI tests, with two marked exceptions. In the youngest group nearly half of the subjects developed CF antibody to V-Swine, while all of them remained without antibody detectable in the HI test. However, when V antigen was used instead of intact virus as hemagglutinin, the post-vaccination sera of these subjects also reacted positively in the HI test. Secondly, a number of prevaccination sera from persons aged 27--50 years possessed CF antibody to A/PR 8 in the: absence of homologous HI antibody. Among these subjects the antibody response to both A/PR 8 and Swine was more marked in the CF test than in the HI test:After vaccine administration most of the subjects developed antibody or responded by an antibody increase to the S antigens of both influenza A and B. No significant differences were found after intradermal (0.1 m]) and subcutaneous (0.5 m l) administration of one dose of vaccine.

show abstract

Respiratory Virus Vaccines

Cited by 7 publications

References 0 publications

Influenza Vaccines Have a Short but Illustrious History of Dedicated Science Enabling the Rapid Global Production of A/Swine (H1N1) Vaccine in the Current Pandemic

Influenza Vaccines Have a Short but Illustrious History of Dedicated Science Enabling the Rapid Global Production of A/Swine (H1N1) Vaccine in the Current Pandemic

Influenza vaccines have a short but illustrious history

Clinical reactivity and immunogenicity of hemagglutinin influenza vaccine

Contact Info

Product

Resources

About